Charles River’s off-the-shelf lentiviral vector packaging plasmids are intended for use with cell and gene therapies.
Charles River Laboratories, a pharmaceutical company specializing in cell and gene therapies, announced the launch of its lentiviral vector (LVV) packaging plasmids on June 13, 2023. According to a company press release, the immediate availability of these off-the-shelf plasmids is intended to provide a streamlined solution for challenges associated with plasmid sourcing for cell and gene therapies, including capacity bottlenecks, timeline pressures, and process development optimization.
“We are thrilled to announce this addition to our product offering,” said Kerstin Dolph, corporate senior vice-president, Biologics Solutions, Charles River, in the release. “Our LVV packaging plasmids allow us to further support advanced therapy programs and most importantly, help expedite the delivery of safe, effective therapies to those who need them most."
“Charles River’s LVV packaging plasmids offer researchers and manufacturers a high-quality, reliable tool to support their LVV viral vectors production,” said Andrew Frazer, associate director, Scientific Solutions, Charles River, in the release. “The new plasmids will be a valuable resource to develop new treatments for a wide range of programs in preclinical and clinical development with the continuity of supply for commercial use”
Source: Charles River
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.